Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives
Advanced hepatocellular carcinoma is a prevalent and potentially aggressive disease. For more than a decade, treatment with sorafenib has been the only approved therapeutic approach. Moreover, no agent has been proven to prolong survival following the progression of disease after sorafenib treatment...
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
MDPI AG
2020-12-01
|
| Edice: | Pharmaceuticals |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/1424-8247/14/1/28 |